{"prompt": "['Appendix 1', 'Schedule of Activities', 'Early', 'Safety', 'Termination /', 'Screening', 'Treatment', 'Follow-up', 'Study', 'Visit', 'Completion', '[a]', 'Wk -4 to', '15 m', '21 m', 'Unscheduled', 'Visits', 'Wk 1', 'Wk 2', 'Wk 3', 'Wk 5', '3 m', '6 m', '9 m', '12 m', '18 m', 'Wk 0', '[b]', '[b]', 'visit', '2 years', 'Time Window,', '+2', '+ 2', '+2', '+7', '+ 7', '+7', '+ 14', '+ 14', '+ 30', '+ 30', '+ 30', 'days', 'Informed consent [c]', 'Inclusion / exclusion', 'X', 'criteria', 'Medical history and', 'X', 'demographics [d]', 'Physical', 'X', 'X', 'X', 'X', 'X', 'examination [e]', 'Vital signs', 'X', 'X', 'X', 'X', 'Concomitant', 'X', 'X', 'X', 'X', 'medications [g]', 'Safety laboratory', 'assessments', 'X', 'X', 'X', 'X', 'Hematology and', 'blood chemistry [h,r]', 'Pregnancy test [i,r]', 'X', 'X', 'X', 'HIV and hepatitis', 'X', 'serology [j]', 'Anti-FVIII antibodies', '*', 'x', 'X', 'X', '[k,r]', 'Emicizumab - F. Hoffmann-La Roche Ltd', '48 / Protocol MO39129, Version 3']['Early', 'Safety', 'Termination /', 'Screening', 'Treatment', 'Follow-up', 'Study', 'Visit', 'Completion', '[a]', 'Wk -4 to', '15 m', '21 m', 'Unscheduled', 'Visits', 'Wk 1', 'Wk 2', 'Wk 3', 'Wk 5', '3 m', '6m', '9 m', '12 m', '18 m', 'Wk 0', '[b]', '[b]', 'visit', '2 years', 'Time Window,', '+ 2', '+2', '+ 2', '+ 7', '+7', '7', '+ 14', '+ 14', '+ 30', '30', '+ 30', 'days', 'Anti-emicizumab', 'X', 'X', 'antibodies [l,r]', 'ePRO bleed /', 'medication', '*', 'X', 'X', 'X', 'X', 'X', 'X', 'x', 'x', 'recording [m]', 'Surgical events [n]', 'X', 'X', 'x', 'X', 'x', 'X', 'x', 'Adverse events [o]', 'x', 'X', 'X', 'X', 'X', 'X', 'IMP -Management of', 'X', 'X', 'emicizumab [p]', 'HRQoL [q]', 'X', 'Health status', 'x', '(EQ-5D-5L) [q]', 'Treatment', 'preference', 'X', 'questionnaire', '(EmiPref) [r]', 'PK assessment [s,t]', 'X', 'X', 'Safety biomarkers', 'X', 'X', 'assessment [s,u]', 'Safety coagulation', 'system biomarkers', 'assessment [s,v]', 'Emicizumab - F. Hoffmann-La Roche Ltd', '49 / Protocol MO39129, Version 3']['Early', 'Safety', 'Termination /', 'Screening', 'Treatment', 'Follow-up', 'Study', 'Visit', 'Completion', '[a]', 'Wk -4 to', '15 m', '21 m', 'Unscheduled', 'Visits', 'Wk 1', 'Wk 2', 'Wk 3', 'Wk 5', '3 m', '6m', '9 m', '12 m', '18 m', 'Wk 0', '[b]', '[b]', 'visit', '2 years', 'Time Window,', '+ 2', '+2', '+ 2', '+ 7', '+7', '7', '+ 14', '+ 14', '+ 30', '30', '+ 30', 'days', 'PD biomarkers', 'X', '*', 'assessment [s,w]', 'Bone and joint', 'biomarker', 'X', '*', 'assessment (fasting)', '[s,x]', 'Additional laboratory', 'assessments [y]', 'For breakthrough bleeds treated with bypassing agents', 'Emicizumab', 'administration', 'Weekly subcutaneous injection', 'd=day; eCRF=electronic Case Report Form; EQ-5D-5L=EuroQoL Five-Dimension-Five Levels Questionnaire; FVIII=Factor VIII; Haem-A-QoL=Hemophilia', 'Adult Quality of Life Questionnaire; Haemo-QoL-SF=Hemophilia Quality of Life Short Form; HIV=human immunodeficiency virus; HRQoL=Health-Related', 'Quality of Life; IMP =investigational medicinal product; m=months (based on calendar months); PD=pharmacodynamic; PK=pharmacokinetic; Wk=week', 'Notes: the maximum allowable time between Screening and enrollment is 4 weeks; if the elapsed time between Screening and enrollment is more than 4', 'weeks, Screening must be repeated.', 'Except for the bleed/medication records, all other patient data will be collected during clinic visits.', 'On treatment days, pre injection blood collection should be made 0 120 minutes before the injection.', 'The', 'same', 'assessments', 'will', 'alse be completed at the Early Termination Visit (if required).', 'a. A safety Follow up Visit will occur 24 weeks after discontinuing emicizumab Patients who discontinue emicizumab prior to the completion of the 2-year treatment', \"period will undergo a Safety Follow-up Visit 24 weeks after the patient's last emicizumab dose or at 2 years after emicizumab treatment start, whichever occurs first.\", 'c.', 'Written informed consent (or patient assent and parent written informed consent, if patient is an adolescent) must be obtained before any study-', 'specific screening procedure tests or evaluations areis performed. For adolescents (i.e., patients who are 12-17 years of age), an Informed Assent Form will be', 'Emicizumab - F. Hoffmann-La Roche Ltd', '50 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}